Arbutus Biopharma
ABUS
80 hedge funds and large institutions have $79.4M invested in Arbutus Biopharma in 2020 Q4 according to their latest regulatory filings, with 28 funds opening new positions, 22 increasing their positions, 12 reducing their positions, and 12 closing their positions.
133% more first-time investments, than exits
New positions opened: 28 | Existing positions closed: 12
83% more repeat investments, than reductions
Existing positions increased: 22 | Existing positions reduced: 12
23% more funds holding
Funds holding: 65 → 80 (+15)
5% more capital invested
Capital invested by funds: $75.5M → $79.4M (+$3.9M)
2.87% less ownership
Funds ownership: 29.12% → 26.25% (-2.9%)
32% less call options, than puts
Call options by funds: $4.67M | Put options by funds: $6.87M
Top Buyers
| 1 |
BlackRock
New York
|
+$2.72M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.77M |
| 3 |
Renaissance Technologies
New York
|
+$1.53M |
| 4 |
Qube Research & Technologies (QRT)
London,
United Kingdom
|
+$1.2M |
| 5 |
Group One Trading
Chicago,
Illinois
|
+$893K |
Top Sellers
| 1 |
FCMI
Foresite Capital Management IV
Larkspur,
California
|
-$10.4M |
| 2 |
Morgan Stanley
New York
|
-$5.21M |
| 3 |
Goldman Sachs
New York
|
-$682K |
| 4 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$400K |
| 5 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
-$139K |
ABUS Hedge Fund Activity: Q4 2020 in Review
80 of the 5,651 institutional investors tracked by Wall St. Rank reported a position in Arbutus Biopharma (ABUS) for Q4 2020, worth a combined $79.4M — up 5.2% from $75.5M a quarter earlier.
Buyers outnumbered sellers: 28 funds opened new ABUS positions and 12 closed out — a net gain of 16 holders — while 22 added to existing stakes and 12 trimmed.
The largest buyer was BlackRock, adding an estimated $2.72M. The largest seller was Foresite Capital Management IV, exiting entirely with an estimated $10.4M sold.
- 80 institutional investors held Arbutus Biopharma (ABUS) as of Q4 2020, up from 65 in Q3 2020.
- Funds reported $79.4M of Arbutus Biopharma stock for Q4 2020, up 5.2% quarter-over-quarter.
- 28 funds opened new Arbutus Biopharma positions in Q4 2020 and 12 closed out, a net change of +16 holders.
- The largest Arbutus Biopharma buyer in Q4 2020 was BlackRock, an estimated $2.72M added.
- The largest Arbutus Biopharma seller in Q4 2020 was Foresite Capital Management IV, an estimated $10.4M sold.
Based on aggregated 13F filings for Q4 2020.